6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Role of MMP8 in Cancer: A Systematic Review

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Matrix metalloproteinases (MMPs) have traditionally been considered as tumor promoting enzymes as they degrade extracellular matrix components, thus increasing the invasion of cancer cells. It has become evident, however, that MMPs can also cleave and alter the function of various non-matrix bioactive molecules, leading to both tumor promoting and suppressive effects. We applied systematic review guidelines to study MMP8 in cancer including the use of MMP8 as a prognostic factor or as a target/anti-target in cancer treatment, and its molecular mechanisms. A total of 171 articles met the inclusion criteria. The collective evidence reveals that in breast, skin and oral tongue cancer, MMP8 inhibits cancer cell invasion and proliferation, and protects patients from metastasis via cleavage of non-structural substrates. Conversely, in liver and gastric cancers, high levels of MMP8 worsen the prognosis. Expression and genetic alterations of MMP8 can be used as a prognostic factor by examination of the tumor and serum/plasma. We conclude, that MMP8 has differing effects on cancers depending on their tissue of origin. The use of MMP8 as a prognostic factor alone, or with other factors, seems to have potential. The molecular mechanisms of MMP8 in cancer further emphasize its role as an important regulator of bioactive molecules.

          Related collections

          Most cited references182

          • Record: found
          • Abstract: found
          • Article: not found

          Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

          The matrix metalloproteinase (MMP) family of enzymes is comprised of critically important extracellular matrix remodeling proteases whose activity has been implicated in a number of key normal and pathologic processes. The latter include tumor growth, progression, and metastasis as well as the dysregulated angiogenesis that is associated with these events. As a result, these proteases have come to represent important therapeutic and diagnostic targets for the treatment and detection of human cancers. In this review, we summarize the literature that establishes these enzymes as important clinical targets, discuss the complexity surrounding their choice as such, and chronicle the development strategies and outcomes of their clinical testing to date. The status of the MMP inhibitors currently in US Food and Drug Administration approved clinical trials is presented and reviewed. We also discuss the more recent and successful targeting of this enzyme family as diagnostic and prognostic predictors of human cancer, its status, and its stage. This analysis includes a wide variety of human cancers and a number of human sample types including tissue, plasma, serum, and urine.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer biomarker discovery and validation.

            With the emergence of genomic profiling technologies and selective molecular targeted therapies, biomarkers play an increasingly important role in the clinical management of cancer patients. Single gene/protein or multi-gene "signature"-based assays have been introduced to measure specific molecular pathway deregulations that guide therapeutic decision-making as predictive biomarkers. Genome-based prognostic biomarkers are also available for several cancer types for potential incorporation into clinical prognostic staging systems or practice guidelines. However, there is still a large gap between initial biomarker discovery studies and their clinical translation due to the challenges in the process of cancer biomarker development. In this review we summarize the steps of biomarker development, highlight key issues in successful validation and implementation, and overview representative examples in the oncology field. We also discuss regulatory issues and future perspectives in the era of big data analysis and precision medicine.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips

              Immunohistochemistry (IHC) is an important auxiliary method for pathologists in routine diagnostic work as well as in basic and clinical research including exploration of biomarkers, as IHC allows confirmation of target molecule expressions in the context of microenvironment. Although there has been a considerable progress in automation and standardization of IHC, there are still many things to be considered in proper optimization and appropriate interpretation. In this review, we aim to provide possible pitfalls and useful tips for practicing pathologists and residents in pathology training. First, general procedure of IHC is summarized, followed by pitfalls and tips in each step and a summary of troubleshooting. Second, ways to an accurate interpretation of IHC are discussed, with introduction to general quantification and analysis methods. This review is not intended to provide complete information on IHC, but to be used as a basic reference for practice and publication.
                Bookmark

                Author and article information

                Journal
                Int J Mol Sci
                Int J Mol Sci
                ijms
                International Journal of Molecular Sciences
                MDPI
                1422-0067
                11 September 2019
                September 2019
                : 20
                : 18
                : 4506
                Affiliations
                [1 ]Cancer and Translational Medicine Research Unit, Faculty of Medicine, University of Oulu, 90014 Oulu, Finland; krista.juurikka@ 123456oulu.fi (K.J.); pia.nyberg@ 123456oulu.fi (P.N.); pirjo.astrom@ 123456oulu.fi (P.Å.)
                [2 ]Medical Research Center Oulu, Oulu University Hospital and University of Oulu, 90220 Oulu, Finland
                [3 ]Department of Oral Biological & Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, BC V6T 1Z2, Canada; george.butler@ 123456ubc.ca
                [4 ]Centre for Blood Research, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
                [5 ]Department of Oral and Maxillofacial Diseases, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland
                [6 ]Helsinki University Hospital, 00014 Helsinki, Finland
                [7 ]Translational Immunology Research Program (TRIMM), University of Helsinki, 00014 Helsinki, Finland
                [8 ]Biobank Borealis of Northern Finland, Oulu University Hospital, 90220 Oulu, Finland
                Author notes
                [* ]Correspondence: tuula.salo@ 123456oulu.fi ; Tel.: +35-840-544-1560
                Article
                ijms-20-04506
                10.3390/ijms20184506
                6770849
                31514474
                bec22480-b9b9-40d4-a847-eb9c265a3866
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 14 August 2019
                : 08 September 2019
                Categories
                Review

                Molecular biology
                matrix metalloproteinase 8,cancer,prognosis,molecular mechanism,cancer drug therapy,systematic review

                Comments

                Comment on this article